SCHEMBL3716262

SCHEMBL3716262

CC(C)(C)OC(=O)NCCSc1ccc(C(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.47
ALDH1A1 P00352 4/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
CYP2C19 P33261 1/20 0.47
MTNR1A P48039 2/20 0.47
MTNR1B P49286 2/20 0.47
MAPT P10636 2/20 0.46
RECQL P46063 1/20 0.46
SDCBP O00560 1/20 0.45
SDC2 P34741 1/20 0.45
GAA P10253 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL445683 0.88 ALDH1A1 (0.48) IDO1ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7528860 0.87 MTNR1A (0.62) IDO1ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7894530 0.86 MTNR1A (0.48) IDO1ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL22015112 0.84 ALDH1A1 (0.53) IDO1ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL18295921 0.84 L3MBTL1 (0.55) IDO1ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL24671054 0.84 IDO1 (0.49) IDO1ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL21013091 0.83 SDCBP (0.47) IDO1ALDH1A1NPC1RAB9ACYP1A2
SCHEMBL20837980 0.82 KMT2A (0.47) IDO1ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL10493769 0.82 IDO1 (0.46) IDO1ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4612706 0.82 IDO1 (0.46) IDO1ALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 WO disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using MTOR, RICTOR, RPTOR IDO1 3511/4885ALDH1A1 3391/4885NPC1 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.